Conclusions: There has been a significant decrease in the proportion of high risk PCIs with elective support device insertion, especially in those performed in patients with acute myocardial infarction in absence of shock. Background: The introduction of new medical devices may be accompanied by a learning curve. Methods: To evaluate the impact of the device learning curve on the outcomes of PROTECT II trial, comparing Impella 2.5 versus the intra-aortic balloon pump (IABP) during high-risk percutaneous coronary intervention, we report on additional analysis excluding not only the first Impella 2.5 and IABP patients at each site but also the first 2 and first 5 patients. Results: A total of 448 patients were enrolled at 74 sites. Among these, 58 patients were the first to receive Impella 2.5 at their site, 62 were the first to receive IABP. After exclusion of the first patient in each group, MAE rates for Impella 2.5 and IABP were 38.0% versus 50.0% (p¼0.029) at 90 days. After excluding the first 2 patients the MAE rates wee 51.7% versus 37.1% and after excluding the first 5 patients the MAE rates were 57.1 versus 37.3%. Conclusions: Significantly lower 90-day MAE rates were observed with the use of Impella 2.5 compared to the use of IABP after excluding the first patient per group at each site. When excluding more patients, the MAE rates change, however, it also drastically reduces the numer of sites included in this analysis. This analysis suggests a learning curve associated with initial introduction of the Impella 2.5. Clinical trials should better address the training aspect of new devices, especially when compared with more established devices. Cedars-Sinai Heart Institute, Los Angeles, CA Background: Use of intra-aortic balloon pump (IABP) in addition to extracorporeal membrane oxygenation (ECMO) for treatment of cardiac failure has become routine in many institutions. However, data is conflicting on whether IABP utilization leads to any incremental clinical benefit on top of ECMO support. Methods: A systematic Medline search was performed for studies reporting on survival to hospital discharge for cardiogenic shock or cardiac arrest requiring ECMO which also reported IABP outcomes. Survival to hospital discharge for patients who received concurrent IABP was compared to those who did not. Outcomes in the incremental use of IABP in acute myocardial infarction, postcardiotomy cardiogenic shock, when placed prior to initiation of ECMO, and in its routine use at initiation of ECMO were also analyzed. Results: Sixteen studies were included in the main analysis encompassing 1,517 patients. The cumulative survival rate for patients on ECMO only was 256/683 (37.5%) compared with 294/834 (35.3%) for patients also supported with IABP. The risk ratio for survival of 1.143 (0.973 -1.343) favored IABP use but was not statistically significant p¼0.105. After removal of one extreme outlier on funnel plot, the risk ratio for survival on reanalysis of 1,430 patients was 1.052 (0.886 -1.249) p¼0.563. The risk ratios for survival for IABP use in acute myocardial infarction and postcardiotomy cardiogenic shock were 1.120 (0.772 -1.624) p¼0.552 and 1.121 (0.826 -1.520) p¼0.463, respectively. The risk ratios for survival for IABP when placed prior to initiation of ECMO or as a routine measure at the initiation of ECMO were 0.948 (0.718 -1.252) p¼0.706 and 1.102 (0.806 -1.506) p¼0.543, respectively. Funnel plot analysis suggested a publication bias in favor of IABP use.
Cedars-Sinai Heart Institute, Los Angeles, CA Background: Use of intra-aortic balloon pump (IABP) in addition to extracorporeal membrane oxygenation (ECMO) for treatment of cardiac failure has become routine in many institutions. However, data is conflicting on whether IABP utilization leads to any incremental clinical benefit on top of ECMO support. Methods: A systematic Medline search was performed for studies reporting on survival to hospital discharge for cardiogenic shock or cardiac arrest requiring ECMO which also reported IABP outcomes. Survival to hospital discharge for patients who received concurrent IABP was compared to those who did not. Outcomes in the incremental use of IABP in acute myocardial infarction, postcardiotomy cardiogenic shock, when placed prior to initiation of ECMO, and in its routine use at initiation of ECMO were also analyzed. Results: Sixteen studies were included in the main analysis encompassing 1,517 patients. The cumulative survival rate for patients on ECMO only was 256/683 (37.5%) compared with 294/834 (35.3%) for patients also supported with IABP. The risk ratio for survival of 1.143 (0.973 -1.343) favored IABP use but was not statistically significant p¼0.105. After removal of one extreme outlier on funnel plot, the risk ratio for survival on reanalysis of 1,430 patients was 1.052 (0.886 -1.249) p¼0.563. The risk ratios for survival for IABP use in acute myocardial infarction and postcardiotomy cardiogenic shock were 1.120 (0.772 -1.624) p¼0.552 and 1.121 (0.826 -1.520) p¼0.463, respectively. The risk ratios for survival for IABP when placed prior to initiation of ECMO or as a routine measure at the initiation of ECMO were 0.948 (0. Methods: This retrospective case series included patients presenting to an academic hospital on inotropes and/or vasopressors who underwent TAVR for inoperable severe AVD. Data collection included morbidity, resource utilization, and immediate procedural mortality (< 72 hours post procedure), 1-month, and 6-month all-cause mortality. Other outcomes collected were based on the standardized endpoint definitions for TAVR of the Valve Academic Research Consortium-2 (VARC-2).
Results: The study cohort consisted of 11 consecutive patients in cardiogenic shock with severe AVD. Most were men (10/11, 90.9%) and the median age was 75 years (IQR 67-85). All patients were on either vasopressors or inotropes prior to the TAVR procedure. The median Society of Thoracic Surgeons Score (STS) for predicted risk of mortality was 32 (IQR: 23-53). There were no operative deaths. Only 1 patient of the 11 (9.1%) had an in-hospital mortality, while 10 (90.9%) survived to discharge. The survival rate at 1 month was 91% (n¼10) and 72.7% (n¼8) at 3 and 6 months. The rate of device success on initial deployment was 91% (n¼10) with 1 patient requiring an emergent but successful TAVR-in-TAVR deployment. The median length of hospital stay was 8 days . Other VARC-2 outcomes included: stroke (n¼0), acute kidney injury (5/11, 45.5%), peri-procedural myocardial infarction (2/11, 18.2%), requirement of TAV-in-TAV deployment (1/11, 9.0%), conduction disturbances (n¼0). Conclusions: In this retrospective, single-institution study, we demonstrate that TAVR appears to be safe and feasible in selected high-risk or inoperable patients with severe AVD and circulatory shock. Furthermore, a multi-institutional trial is needed to evaluate the safety and feasibility of TAVR in this high-risk patient population.
TCT-72
Timing of Intra-aortic Balloon Therapy in ST Elevation Myocardial Infarction Background: Cardiogenic shock (CS) occurs in up to 25% of patients with ST elevation myocardial infarction (STEMI). Use of peripheral ventricular assist device (p-VAD) such as intra aortic balloon pump (IABP) is recommended in these patients. However, there is conflicting evidence regarding the timing of initiation of IABP therapy in STEMI patients with CS. We aimed to determine if there was a difference in outcomes between patients who had initiation of IABP therapy in STEMI patients, pre-and post-percutaneous coronary intervention (PCI). Methods: Medical records of 613 consecutive patients undergoing primary PCI for STEMI were screened to identify 174 patients receiving IABP therapy. Baseline clinical and outcome data were compared between those receiving IABP pre (n¼76) and post PCI (n¼98). Results: Post-PCI IABP group had a higher association with ventricular arrhythmia (p¼0.05), use of defibrillation (p¼0.04), refractory shock (p¼0.05), cardiac arrest during hospitalization (p¼0.05), and death at 1 year post index event (p¼ 0.05). (Table 1 ) On logistic regression model using significant baseline variables as covariates, refractory shock retained its association with post-PCI IABP placement (p¼0.005). Conclusions: In patients with STEMI with CS, pre-PCI initiation of IABP therapy led to fewer cases of refractory shock without affecting the door to balloon times, indicating that early myocardial unloading improves overall clinical outcomes in STEMI patients.
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A Systematic review and meta-analysis of emergency coronary angiography and percutaneous coronary intervention in patients who present with cardiac arrest. Should we implement a standard invasive approach? Background: Because of limited data, the indications and timing of coronary angiography (CAG) and percutaneous coronary intervention (PCI) in patients with cardiac arrest are controversial. In clinical practice it is often difficult to determine which patients benefit from early catheterization, with subsequent PCI. The guidelines promote early catheterization in cardiac arrest patients with ST-elevation myocardial infarction. However, the predictive value of the ECG for coronary artery occlusion is poor, especially after cardiopulmonary resuscitation. Methods: Medical literature databases were scrutinized to identify randomized trials comparing CAG vs. no CAG, and PCI vs. no PCI. In absence of randomized trials cohort studies evaluating emergency CAG and PCI in cardiac arrest were identified. Two separate meta-analyses were performed respectively. Results: The first meta-analysis included 16 cohort studies of patients with cardiac arrest (n¼7709). Early CAG compared to no CAG was associated with an absolute decrease of in-hospital mortality of 14% [95% confidence interval (CI), 12-16%; P< 0.0001]. This survival benefit was also observed in subsequent subgroup analysis, respectively of patients with STEMI or new LBBB, and patients with other ECG patterns. The second meta-analysis included 11 cohort studies evaluating the effect of emergency PCI in cardiac arrest patients (n¼3033). Emergency PCI compared to no PCI was associated with an absolute decrease of in-hospital mortality of 18% [95% CI 14-22%; P< 0.0001]. Conclusions: Both early CAG and PCI, compared to respectively no CAG and PCI were associated with a survival benefit in patients presenting with cardiac arrest. This did not differ between patients with STEMI or new LBBB, and patients with other ECG patterns. The prevalence of coronary heart disease, regardless of presenting ECG pattern, is high. All available observational data evaluating early CAG and PCI is importantly hampered by bias and confounding; i.e. survival and physician selection bias. Nonetheless, the results of this study support further evaluation of a more a more aggressive CAG and PCI strategy than currently advocated.
TCT-74
Use of Impella 2.5 for Electrical Stabilization in Acute Myocardial Infarction Background: The efficacy of Impella (Abiomed Inc., MA, USA) for electrical instability in the setting of an acute ST-elevation myocardial infarction (STEMI) is unknown. Herein, we present a case series of successful hemodynamic support and electrical stabilization by an Impella device in the setting of ischemic cardiogenic shock. Methods: Both patients received guideline-directed medical therapy for STEMI and support with aggressive fluid resuscitation, intubation and inotropes. Intra-aortic balloon pump and Impella devices were inserted through the femoral approach. Results: A 67-year-old female suffered an acute inferior STEMI with cardiogenic shock from severe right heart failure. During revascularization, she developed multiple episodes of ventricular tachycardia (VT)-fibrillation (VF) despite amiodarone infusion. In light of her hemodynamic and electrical cardiac instability, an intra-aortic balloon pump (IABP) was inserted. However, she remained in right ventricular (RV) shock (cardiac index of 1.8 L/min/m2) and required a total of 27 defibrillations. A decision was made to insert an Impella 2.5 as a bridge to RV recovery, with dramatic hemodynamic and electrical response. Device was successfully removed the following day and she recovered well. A 52 year old male was admitted in cardiogenic shock secondary to an anterior wall STEMI. Cardiac catheterization revealed a complete occlusion of the left anterior descending coronary artery. The patient received an IABP due to hemodynamic instability. He subsequently required more than 20 defibrillations for VT/VF. The IABP was replaced by an Impella 2.5 device. The patient was quickly restored to sinus rhythm after Impella in place. The device was removed 4 days after the procedure and the patient recovered well. Conclusions: We report two cases of severe electrical instability with recurrent VT/ VF in the setting of cardiogenic shock secondary to an acute myocardial infarction. In this limited experience, the Impella left ventricular assist device was able to achieve electrical stability more effectively when compared to an intra-aortic balloon pump.
Heart Failure Therapies
Washington Convention Center, Lower Level, Hall A Saturday, September 13, 2014, 5:00 PM-7:00 PM
